To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together
This study has been completed.
Sponsor:
Astellas Pharma Inc
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT01478568
First received: November 21, 2011
Last updated: NA
Last verified: November 2011
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study aims to evaluate if blood levels of desipramine change whilst being dosed at the same time with daily mirabegron.
| Condition | Intervention | Phase |
|---|---|---|
|
Pharmacokinetics of Mirabegron Healthy Subjects |
Drug: mirabegron Drug: desipramine |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Pharmacokinetics Study Intervention Model: Crossover Assignment Masking: Open Label |
| Official Title: | An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of the CYP2D6 Substrate Desipramine in Healthy Subjects |
Resource links provided by NLM:
Further study details as provided by Astellas Pharma Inc:
Primary Outcome Measures:
- Pharmacokinetics of desipramine assessed by plasma concentration while at steady state levels of mirabegron [ Time Frame: Pre-dose until 72 hours after dosing ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Monitoring of safety and tolerability through assessment of vital signs, ECG, clinical safety laboratory and adverse events [ Time Frame: Baseline until End of Study Visit (7 to 14 days after last dose) ] [ Designated as safety issue: Yes ]
- Pharmacokinetics of desipramine assessed by plasma concentration after wash-out of mirabegron [ Time Frame: Pre-dose until 72 hours after wash-out ] [ Designated as safety issue: No ]
| Enrollment: | 28 |
| Study Start Date: | October 2008 |
| Study Completion Date: | January 2009 |
| Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: mirabegron / desipramine |
Drug: mirabegron
oral
Other Name: YM178
Drug: desipramine
oral
Other Names:
|
Detailed Description:
This is an open-label, one-sequence crossover design study to evaluate the drug-drug interaction between mirabegron and desipramine. The effect of mirabegron on the plasma concentration of desipramine will be evaluated after 13 day repeated administration. The recovery of CYP2D6 activity is also being explored by comparing the pharmacokinetic profiles of desipramine after a 2 week wash-out period.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Body Mass Index between 18.5 and 30.0 kg/m2 inclusive
- Subject is genotyped and phenotyped as an extensive metabolizer for CYP2D6
Exclusion Criteria:
- Known or suspected hypersensitivity to YM178 or any of the components of the formulation used
- Known or suspected hypersensitivity to desipramine or any of the components of the formulation used
- Pregnant or breast feeding within 6 months before screening assessment
- Any clinical history of major depressive disorder, cardiovascular disease, urinary retention, glaucoma, thyroid disease and/or seizure disorder
- Any of the liver function tests (i.e. Alanine Aminotransferase (ALT), Asparate Aminotransferase (AST) and Alkaline phosphatase) above the upper limit of normal at repeated measurements
- Any clinically significant history of asthma, eczema, any other allergic condition or previous severe hypersensitivity to any drug (excluding non-active hay fever)
- Any clinically significant abnormality following the investigator's review of the pre-study physical examination, ECG and clinical laboratory tests
- Abnormal pulse rate and/or blood pressure measurements at the pre-study visit as follows: pulse rate <40 or >90 bpm; mean systolic blood pressure >140 mmHg; mean diastolic blood pressure >90 mmHg (blood pressure measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse rate will be measured automatically)
- A marked baseline prolongation of QT/QTc interval after repeated measurements of >450 ms, a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS)
Contacts and Locations More Information
No publications provided
| Responsible Party: | Astellas Pharma Inc |
| ClinicalTrials.gov Identifier: | NCT01478568 History of Changes |
| Other Study ID Numbers: | 178-CL-058, 2008-000215-15 |
| Study First Received: | November 21, 2011 |
| Last Updated: | November 21, 2011 |
| Health Authority: | United States: Food and Drug Administration France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by Astellas Pharma Inc:
|
Pharmacokinetics Mirabegron Phase 1 |
Additional relevant MeSH terms:
|
Desipramine Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antidepressive Agents, Tricyclic Antidepressive Agents Psychotropic Drugs |
Central Nervous System Agents Therapeutic Uses Adrenergic Uptake Inhibitors Adrenergic Agents Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 18, 2013